Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

Complement Factor H (CFH) is a pivotal regulator of the complement system, integral to maintaining immune homeostasis and protecting host tissues from undue complement‐mediated damage. By inhibiting ...

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

Nanomedicine uses ultra-small particles to deliver drugs directly to the tissues and cells that need them, improving ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...